NaiVec Signs Gene-Based Drug Delivery Material Transfer Agreement with Global Pharmaceutical Company
[Asia Economy Reporter Yoo Hyun-seok] Nivec announced on the 17th that it has signed material transfer agreements with global pharmaceutical companies and biotech firms for gene drug delivery systems such as 'mRNA'. If Nivec's gene drug delivery technology succeeds in commercialization, it is expected to improve vaccine safety by eliminating the need for ultra-low temperature storage of COVID-19 vaccines and reducing side effects.
In January, at the JP Morgan Conference, following the presentation of research results on peptide-based anticancer treatments, Nivec introduced its gene drug delivery platform (NIPEP-TPP) technology and engaged in discussions with global pharmaceutical companies regarding technology adoption.
The gene drug delivery platform is a technology that can accurately deliver large molecular gene medicines such as 'mRNA' to targeted lesion sites without side effects.
During discussions on technology adoption with global pharmaceutical companies, Nivec provided all data related to NIPEP-TPP’s drug delivery, therapeutic effects, production, and safety. The pharmaceutical companies completed verification of the data and evaluated Nivec’s gene delivery technology as highly effective.
In particular, among COVID-19 vaccines, those adopting the lipid nanoparticle (LNP) method require ultra-low temperature freezing facilities at -80℃, but Nivec’s gene drug delivery technology is regarded as a next-generation solution capable of overcoming this limitation.
A Nivec official stated, "COVID-19 vaccines based on lipid nanoparticles have raised significant safety concerns due to unwanted allergic reactions after administration, and pharmaceutical companies producing vaccines are in urgent need of developing new formulations. Nivec’s gene drug delivery technology delivers the drug precisely to the target site, which has been verified in animal experiments, attracting strong interest from vaccine-producing pharmaceutical companies."
He added, "Due to confidentiality agreements, we cannot disclose the names of the pharmaceutical companies, but they are considering applying this technology not only to vaccine therapeutics but also to gene therapy fields including CAR-T for rare diseases. Nivec’s possession of cGMP-grade synthesis facilities allows for uninterrupted supply of materials not only in preclinical but also post-clinical stages, which was positively evaluated as it can accelerate commercialization."
Hot Picks Today
Taking Annual Leave and Adding "Strike" to Profiles, "It Feels Like Samsung Has Collapsed"... Unsettled Internal Atmosphere
- There Is a Distinct Age When Physical Abilities Decline Rapidly... From What Age Do Strength and Endurance Drop?
- "One Comment Could Lead to a Report": 86% of Elementary Teachers Feel Anxious; Half Consider Resignation or Career Change
- "After Vowing to Become No. 1 Globally, Sudden Policy Brake Puts Companies’ Massive Investments at Risk"
- On Teacher's Day, a Student's Gifted Cake Had to Be Cut into 32 Pieces... Why?
Nivec explained that following the JP Morgan Conference, urgent data transfers and subsequent discussions have been actively taking place, and related pharmaceutical companies are proactively pursuing technology adoption to the extent that business model discussions for collaboration are underway.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
